PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Cellular Signalling
- Vol. 50, 72-79
Abstract
No abstract availableKeywords
Funding Information
- US Public Health Service (R01 CA095621)
- National Institutes of Health (R01 HL082959)
This publication has 45 references indexed in Scilit:
- Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell SurvivalPLOS Biology, 2013
- The Immediate Early Gene Product EGR1 and Polycomb Group Proteins Interact in Epigenetic Programming during ChondrogenesisPLOS ONE, 2013
- Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemiaLeukemia, 2013
- The functions and regulation of the PTEN tumour suppressorNature Reviews Molecular Cell Biology, 2012
- PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia AngiogenesisAdvances in Hematology, 2012
- CREB Is a Novel Nuclear Target of PTEN PhosphataseCancer Research, 2011
- Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common β-subunitBlood, 2010
- The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in diseaseBlood, 2009
- PTEN regulation by Akt–EGR1–ARF–PTEN axisThe EMBO Journal, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008